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Abstract The use of animals as a source of organs and
tissues for xenotransplantation can overcome the growing
shortage of human organ donors. However, the presence of
xenoreactive antibodies in humans directed against swine
Gal antigen present on the surface of xenograft donor cells
leads to the complement activation and immediate xenograft
rejection as a consequence of hyperacute reaction. To pre-
vent hyperacute rejection, it is possible to change the swine
genome by a human gene modifying the set of donor’s cell
surface proteins. The gene construct pGal-GFPBsd containing
the human gene encoding !-galactosidase enzyme under the
promoter of EF-1! elongation factor ensuring systemic expres-
sion was introduced by microinjection into a male pronucleus
of the fertilised porcine oocyte. As a result, the founder male
pig was obtained with the transgene mapping to chromosome
11p12. The polymerase chain reaction (PCR) analysis revealed
and the Southern analysis confirmed transgene integration
estimating the approximate number of transgene copies as
16. Flow cytometry analysis revealed a reduction in the level
of epitope Gal on the cell surface of cells isolated from F0 and
F1 transgenic animals. The complement-mediated cytotoxicity
assay showed increased viability of the transgenic cells in
comparisonwith thewild-type, which confirmed the protective
influence of α-galactosidase expression.
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Introduction
Decreasing the frequency of chronic graft rejections, de-
creasing the toxicity of immunosuppressive treatments, in-
ducing tolerance, and ensuring a sufficient number of graft
organs are currently the most important challenges of mod-
ern transplantology. While the number of people awaiting
transplantation is increasing every year, the availability
of organs for transplantation is limited. In 2011, according
to the Organ Procurement and Transplantation Network
(OPTN), the number of registered donors in the United States
of America was 11,713 (including living donors, which con-
stituted 42.12 %), and the number of patients awaiting trans-
plantation was 112,728. There was a total demand for 122, 438
organs, while the number of transplantations was only 23,745.
For example, 16,857 patients awaited liver transplantation,
while the available organs could cover only 34.34 % of the
demand. In fact, in 2011, 5,288 liver transplantations were
conducted in 31 % of awaiting patients (OPTN 2011). The
introduction of improvements in the system of organ registra-
tion and distribution and better general health of the society
obtained through promoting healthy lifestyle are not enough to
improve the short supply of potential organs and transplanta-
tion tissues. This situation resulted in increased interest
in studies on alternative sources of organs. Transplantation
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involving the use of organs from other mammals as human
transplants are called xenotransplantation. They have become
the most obvious strategy of solving the problem and a chance
to save lives.
From both the genetic and physiological points of view,
the phylogenetic proximity of apes and humans is the stron-
gest argument standing for xenotransplantations. However, it
is also one of the biggest obstacles, involving the risk of
infections, particularly with animal viruses. Due to the large
phylogenetic distance and similar anatomical and physiolog-
ical parameters, especially in respiratory and circulatory
systems, choosing pigs as a donor of tissues and organs for
transplantation seems to be justifiable. The size diversity
between different types of pigs allows for choosing organs
of size adjusted to different recipients. Pigs, as an easy-
breeding species, can be housed under strict barrier condi-
tions and screened for pathogenic xenozoonosis at regular
intervals (Cooper 2012). However, it should be expected
that the large phylogenetic distance will be the reason for a
number of immunological complications after pig-to-human
transplantations. Binding the naturally occurring preformed
antibodies of recipient to Gal!(1,3)Gal epitopes on the en-
dothelial surface makes apes reject grafts from pigs by means
of hyperacute rejection (HAR). The Galα(1,3)Gal epitope
is formed by connecting a molecule of galactose to N-
acetyllactosamine by the 1,3-glycosidic bond in the presence
of !1,3-galactosyltransferase (GGTA1, !1,3GT) (Sandrin and
McKenzie 1994). Both the enzyme and the sugar residue are
not present in humans and apes of the Old World (Galili et al.
1988). It is suggested that, in ancestors of order primates, the
gene coding for 1,3-galactosyltransferase was inactivated
(Galili and Swanson 1991). Humans have, in turn, xenoreactive
antibodies (XNA), which recognise the Gal!(1,3)Gal epitope
present on several dozens of molecules on the surface of
endothelial cells in the pig and activate the enzymatic cascade
of the complement system responsible for rapid graft rejection.
Among all xenoreactive antibodies in the human organism,
even 90 % recognise the Galα(1,3)Gal epitope. Anti-Gal anti-
bodies constitute approximately 1–2.4 % of IgG and 1–8 % of
IgM immunoglobules circulating in human blood (Sandrin
et al. 1993; McMorrow et al. 1997). One of the factors of
preventing the rejection of xenografts is to develop methods
of controlling or limiting the hyperacute rejection of the immu-
nological system through, inter alia, decreasing the amount of
Gal!(1,3)Gal epitopes on the surface of donor cells. This prob-
lem can be overcome by the development of pigs homozygous
for !1,3-galactosyltransferase gene-knockout (GTKO). If dom-
inant pig carbohydrate and glycoprotein epitopes other than
Gal!(1,3)Gal are shown to be physiologically pivotal in the
pig-to-human combination, additional gene knockouts could
also be envisioned (Pierson 2009). Another strategy is to use
digestion to remove terminal residues of epitope D-galactose
from the surface of pig cells by specific !-galactosidase (GLA)
(Luo et al. 1999). The use of GLA isolated from coffee seeds
decreased the cytotoxic activity of natural antibodies present in
both human serum and crab-eating macaque by 59–90 % in
relation to endothelial cells of the pig (SEC) (LaVecchio et al.
1995). The perfusion of organs with GLA requires isolating and
purifying significant amounts of enzyme and maintaining opti-
mal conditions for its activity, which, in consequence, generates
costs, making it hardly usable on a broader scale (Ogawa et al.
2000). Vast progress in obtaining transgenic livestock resulted
in the possibility of remodelling the genome of the pig for
xenotransplantations through the introduction of gene coding
for humanα-galactosidase. The expression of human GLAwas
obtained in studies on pig cell lines. The result was a 30-fold
decrease in the level of Galα(1,3)Gal epitope on the endo-
thelial surface (Osman et al. 1997). A reduction in the
amount of Gal!(1,3)Gal epitope was observed in similar
studies with the use of COS cells and NIH 3T3 (Yan et al.
2003); however, !-galactosidase does not remove the resi-
dues of D-galactose from the Gal antigen entirely. At the
same time, it is suggested that, in the case of isolated enzymes,
GLA and !1,2-fucosyltransferase (!1,2FT) coexpression is
used. The enzyme !1,2-fucosyltransferase competes with
!1,3-galactosyltransferase, which is responsible for the syn-
thesis of Gal!(1,3)Gal epitope, for the same substrate, N-
acetyllactosamine (N-lac), catalysing the addition of fucose,
which results in the formation of the so-called H structure,
commonly present in mammals (Larsen et al. 1990; Sandrin
et al. 1995). The additive effect of both enzymes resulting in
the total elimination of Gal antigen expression on the cell
surface was observed in the case of cotransfection of different
types of cells with genes coding for GLA andα1,2FT (Osman
et al. 1997; Yan et al. 2003; Jia et al. 2004).
The aim of this study was to prepare an expressive pGal-
GFPBsd gene construct containing the sequence coding for
enzyme !-human galactosidase controlled by the promoter of
EF-1! elongation factor ensuring the systemic expression of
transgene and introducing it to the genome of pig by micro-
injection. In this study, we present the results characterising
transgenic pigs with human α-galactosidase expression using
molecular, cytogenetic and functional approaches. The results
are confronted with data obtained for TG1154 transgenic pig
with !1,2-fucosyltransferase expression (Lipiński et al. 2010)
in order to conduct cumulative transgenesis in the future for
cumulating the activity of both enzymes in one organism for
the needs of xenotransplantation.
Materials and methods
Gene construct
The pGal-GFPBsd gene construct was obtained by introduc-
ing cDNA coding for !-galactosidase (1,290 bp) into a
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pTracer-EF/Bsd A (5,987 bp) plasmid containing a strong,
constitutive promoter of 1! subunit of human elongation
factor EF (hEF-1!) (1,179 bp) and a poly(A) sequence of
cattle GH gene (225 bp). Vector pTracer-EF/Bsd A expresses
the blasticidin resistance gene as a fusion product with the
Cycle 3 GFP, allowing the selection and non-invasive detec-
tion of recombinant proteins (Invitrogen). The coding se-
quence was amplified on single-strand cDNA template
synthesised by oligo(dT)20 primers and the SuperScript III
kit (Invitrogen). Total RNA was isolated from human white
blood cells from peripheral blood with the method based on
guanidine isothiocyanate (Chomczynski and Sacchi 1987).
Modified primers were used for amplification. Additionally,
a sequence recognised by the EcoRI enzyme (5′-GCGAA
TTCCATGCAGCTGAGGAACCCAGAACTACA-3′) was
placed in the F primer and a sequence recognised by the
NotI enzyme (5′-GGCGGCCGCTTAAAGTAAGTCTTT
TAATGACATCTGCA-3′) was placed in the R primer.
Polymerase chain reaction (PCR) of 25 μl was conducted
in the following conditions: 94 °C, 60 s; 58 °C, 60 s; 72 °C,
90 s; 35 cycles. The reaction mixture contained 1 μl of
cDNA, 10 pM of primers, 7.5 nM dNTP, 1× buffer and 1 U
of DNA Taq polymerase (Sigma). PCR product was digested
by EcoRI (Fermentas) and NotI (Fermentas), purified and
ligated with the pTracer-EF/Bsd Avector, which was digested
with the same endonucleases. The product was sequenced
using automated genetic analysers (Applied Biosystems
Prism). The construction prepared for microinjection was
purified by the PureLink™ HiPure Plasmid DNA Maxiprep
Kit (Invitrogen) and then linearised with the Eam1105I
enzyme.
Microinjection
Exogenous DNA as a pGal-GFPBsd gene construct was
inserted into the male pronucleus of a fertilised egg cell.
Microinjection was performed with the use of two microma-
nipulators under a reverse microscope with differential inter-
ference contrast. The applied magnification was objective
40× X eyepiece = 450×. DNA was injected into the male
pronucleus with the use of an injector or a syringe connected
to the holder for a manipulator. The volume of inserted DNA
was 2–5 pl. DNA was inserted until the moment when the
pronucleus increased its volume by 50 %. The DNA con-
centration was 2–4 ng/μl. After the injection, the damaged
zygotes were removed. Selected zygotes with the GFP signal
detected were transplanted into the fallopian tubes of
synchronised recipients.
Screening of transgene
Analysis included genomic DNA isolation from biopsies of
potentially transgenic animals with the use of proteinase K.
PCR was conducted on DNA template. Two pairs of primers
were used for amplification. Both F primers were complemen-
tary to the hEF-1! promoter sequence, and both R primers
were complementary to the sequence of !-galactosidase
(Fig. 1). A PCR product of 464 bp is formed with the use of
the first pair of F1 (5′-GGGGAGGGGTTTTATGCGATG
GAG-3′) and R1 (5′-CTGGCTCTTCCTGGCAGTCA-3′)
primers, whereas a second product of 861 bp is formed with
the use of the F2 (5′-ACCAGTTGCGTGAGCGGAAAG
ATG-3′) and R2 (5′-GGCGAATCCCATGAGGAAAG-3′)
primers. PCR was conducted in 20 μl in the following condi-
tions: 94 °C, 40 s; 60 °C, 30 s; 72 °C, 60 s; 35 cycles. The
reaction contained 100 ng of genomic DNA, 10 pM of
primers, 7.5 nM of dNTP, 1× buffer and 1 U of DNA Taq
polymerase (Sigma).
Southern hybridisation analysis
For Southern analysis, total genomic DNA from the wild-
type and analysed transgenic pig was extracted from white
blood cells from peripheral blood with the method based on
guanidine isothiocyanate. 5.6 μg of each DNAwas digested
with restriction enzyme EcoRI and hybridised with a probe
of 464 bp. The probe was a 32P-dATP-labelled PCR product
of 464 bp formed on plasmid DNA (pGAL-GFPBsd) with
the use of the first pair of primers (F1 and R1) used for the
integration analysis (described above). The EcoRI enzyme
digests the genomic DNA of pig as well as the pGAL-
GFPBsd sequence (only one site). Digestion of the pGAL-
GFPBsd sequence with EcoRI gives a fragment of 7.3 kb that
is identical to the size of the introduced genetic construct.
Additionally, for determining the transgene copy number, to
the digested DNA of wild-type pig, known amounts of
plasmid-containing transgene insert DNAwas added. Then,
DNA samples were electrophoresed using 1 % agarose gel in
1 × TBE, 40 V overnight. Denatured and neutralised DNA
immobilised in dried gel was hybridised to a transgene-
specific probe overnight (55 °C, 5 × SSPE, 0.1 %SDS).
Determination of the absolute number of transgene copies
in transgenic pigs
Since 1 ng of DNA corresponds to the molecular mass of
606,060,600 MDa and the molecular mass of the swine ge-
nome amounts to 1,820,000 MDa, therefore, 1 ng of swine
genomic DNA contains approximately 333 copies of the
genome. 5.6 μg of swine genomic DNA sample per gel line
were used, hence, each of the examined samples contained
about 1,864,800 copies of the swine genomic DNA. In order
to calculate the number of copies of the transgene incorporat-
ed into a single genome of transgenic animals, the absolute
number of copies of the transgene in titration samples (respec-
tively, 124,122,350, 62,061,175, 31,030,587, 15,515,293,
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7,757,646 copies) was divided by the number of copies of the
genomic DNA. In the case of heterozygotic transgenic ani-
mals, the transgene occurs only on one of the pair of homo-
logue chromosomes; therefore, in order to calculate the num-
ber of transgene copies built into one of the chromosomes, the
result obtained from the calculations was multiplied by 2.
Skin fibroblasts isolation and cultivation
The experimental material comprised skin fibroblasts
obtained from the tissues of wild-type and transgenic pigs.
Sterile tissues were rinsed in PBS solution containing antibi-
otics (50 μg/ml gentamicin sulphate, 100 IU penicillin and
50μg/ml streptomycin). Skin fragments were cut and digested
in 5 ml trypsin-EDTA solution in PBS and then centrifuged.
The cell sediment was suspended in enriched DMEMmedium
(20 % FBS, 1 % antibiotic/antimycotic; Sigma). Culturing
was carried out at the temperature of 37 °C at 5 % CO2
content. Transgenic cultures were checked for GFP signal.
Cultures of full confluence were passaged to new 25 cm2
culture flasks.
Mapping of the pGal-GFPBsd transgene
Transgene mapping was conducted by fluorescent in situ
hybridisation (FISH) with the use of in-vitro-cultivated cell
lines. Pig karyotype evaluation was performed before
conducting FISH. It involved the trypsinisation of chromo-
some preparations with trypsin and staining them with
Giemsa stain solution. The obtained chromosome bands
were analysed with the use of a microscope with a camera
and appropriate software (Ikaros, MetaSystems). FISH was
used for random primer hybridisation of the pGal-GFPBsd
gene construct into the metaphase chromosomes obtained
earlier. Hybridisation was conducted at 37 °C for 17 h.
Signal detection was performed with the use of antibodies
against biotin and detected by fluorescein. In order to enable
observation under a fluorescent microscope, DAPI/Antifade
was used for dying. The image analysis was performed with
the use of an Olympus 3X41 fluorescent microscope and the
digital image analysis system MetaSystems 4000 ISIS
Version 5.0. Transgene location was determined based on
the standardised domestic pig karyotype (Gustavsson 1988).
Flow cytometry
Having reached full confluence, the skin fibroblasts cultivat-
ed in vitro were washed with Hanks solution and trypsinised
(0.25 % trypsin, 0.02 % EDTA). Fibroblasts were collected
by centrifugation. The cells were suspended and incubated in
PBS containing lectin (10 μg/ml) and 5 % FBS, at 4 °C, for
45 min. Lectin BS-IB4 isolated from Griffonia simplicifolia
(Bandeiraea simplicifolia) conjugated with AlexaFluor 647
fluorochrome (Invitrogen) was used for the specific detec-
tion of Gal epitope. The flow cytometer (cell sorter) BD
FACS Aria™III (Becton Dickinson) with four lasers
(375 nm, 405 nm, 488 nm and 633 nm), 11 fluorescence
detectors and dispersed laser light detectors–forward scatter
(FSC) and side scatter (SSC) were used for the analysis of
Gal epitopes on the surface of examined cells. Optical align-
ment and functional stability tests were conducted with the
CST system (Cytometer Setup and Tracking; Becton
Dickinson). FACSFlow (Becton Dickinson) was used as
the sheath fluid. The following cytometer configuration
was applied: 85 μm cell sorting nozzle and sheath fluid
pressure of 45 psi. The characteristics of cells were obtained
based on two non-fluorescent parameters, FSC and SSC, and
one fluorescent parameter, red fluorescence (FL1 detector),
from the AlexaFluor 647 fluorochrome, with detection
obtained by the use of a 660/20 optical filter. Red laser
(633 nm) was used for AlexaFluor 647 fluorochrome exci-
tation. Cytometric analysis was conducted based on specific
detector settings, which convert the collected signals into a
logarithmical scale. The FSC detector was equipped with an
optical filter of neutral density in order to weaken the dis-
persed light reaching it and enable conversion of the popu-
lation of analysed cells on a two-dimensional scale to a graph











Fig. 1 The scheme shows the gene construct pGal-GFPBsd encompassing
a strong, constitutiveEF-1! promoter (1,179 bp), cDNAof the gene coding
for human !-galactosidase (1,290 bp) and the poly(A) sequence of the
cattle GH gene (225 bp).Moreover, the vector contains the sequence of Bsd
gene coding for blasticidin antibiotic resistance joined with the GFP
sequence under the control of the CMV promoter. The scheme also shows
the locations of the primers used for the screening of the transgene (F1 and
R1, F2 and R2) and the Southern probe binding site (between F1 and R1
primers)
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threshold was set at the signal of the FSC detector. The data
presented on the logarithmical scale were divided into four
decades in the form of the signal surface from different
detectors (FSC-A, SSC-A and FL1-A) and analysed with
the use of FACS DIVA software (Becton Dickinson). The
analysis of fluorescence signals preceded the doublets dis-
crimination procedure with the use of height versus width
scatter signals measurement, in order to discriminate single
events (cells) from conglomerates. The populations were
then defined by gating in the dot plots of red fluorescence
(FL1) versus side scatter signals (SSC). Each sample was
analysed four times. Determining the levels of Gal epitope
on the surface of the analysed cells was conducted based on
the median values of fluorescence signals from the FL1
detector in populations defined on a two-dimensional graph
(FL1 and SSC).
Human serum cytotoxicity test
Having reached full confluence, the skin fibroblasts cultivat-
ed in vitro were rinsed with Hanks solution and trypsinised.
The fibroblasts were collected by centrifugation and the
debris was washed with Hanks solution and suspended in
200 μl of one of three mediums: (A) 50 % DMEM and 15 %
FBS in PBS, basic medium; (B) 50 % HS (human serum) in
PBS, test medium; (C) 50 % thermally inactivated HS in
PBS, control medium. The cells were incubated at 37 °C for
30 min. Then, 20 μl of 0.4 % trypan blue was added to 20 μl
of cell suspension and incubated for 5 min at room temper-
ature. Living and dead cells were counted in Bürker’s cham-
ber with a volume of 0.9 mm3. Cells that were over or
touching the top and left line of each square of 1 mm2 were
counted, while the cells that were over or touching the
bottom or right line were ignored. Each analysis was repeat-
ed 12 times. The percentage of living cells was calculated for
each repetition. Then, the average numbers of living cells,
dead cells and all cells from 12 repetitions were calculated.
Results
Obtaining transgenic pigs with α-galactosidase expression
The pGal-GFPBsd gene construct was obtained by introduc-
ing cDNA coding for α-galactosidase into a pTracer-EF/Bsd
A plasmid. The correctness of the gene construct was con-
firmed by sequencing. The prepared pGal-GFPBsd gene
construct (Fig. 1) was introduced based on the standard
method of microinjection into one of the pronuclei of the
zygote. 580 fertilised egg cells from 48 donors were
subjected to microinjection. 529 zygotes were transplanted
into the fallopian tubes of synchronised recipients (average
of 33 zygotes/animal). From eight recipients, 37 piglets were
obtained in the F0 generation, which were subjected to DNA
analysis in order to detect the transgene by PCR. The anal-
ysis showed that one male piglet in the F0 generation
(TG252) incorporated the transgene (1/37; 2.7 %) (Fig. 2a).
When the male TG252 reached puberty, its sperm was used
for the artificial insemination (AI) of wild-type sows. As a
result of AI, 75 piglets have been obtained so far, among
which 12 were transgenic (12/75; 16 %). Changes in the size
of the products analysed by PCR were not observed in
transgenic pigs from the F1 generation, which means that
the transgene is stably integrated with the genome and
passed between consecutive generations (Fig. 2b). To con-
firm transgene integration, we conducted Southern analysis
for all transgenic animals, which confirmed the presence of
transgene in all of them. We show the results for TG252 (F0)
and three representatives of the F1 generation, TG1183,
TG1036 and TG1040, in Fig. 3. By using known concentra-
tions of the transgene mixed with wild-type DNA, we were
able to estimate the copy number in each of the animals. In
the current analysis, the approximate number of transgene
copies integrated was estimated as 16.
From screening by Southern analysis, it can be deter-
mined that transgene is present, intact, in how many copies
and what orientation. Neither of the other commonly used
techniques yielded nearly the same amount of information.
PCR analysis does not allow to quantify the copy number
and, usually, can only confirm the presence of the transgene
and cannot provide information as to either the intactness or
orientation of the transgene. Despite its limitations, the tech-
nique is useful as a preliminary screening method. The use of
PCR allows the identification of potential transgenic animals
and reduces the number of samples for Southern analysis
(Tinkle and Jay 2002).
Cytogenetic analysis
Karyotype evaluation of the transgenic animals was performed
by the Giemsa method. The obtained pattern of bands on
chromosomes was analysed and compared with the standard
karyotype of domestic pig. The number, structure and archi-
tecture of chromosomes were unaffected in both the F0
(TG252) and F1 (TG1183) generations (Fig. 4a, b). In both
generations (F0 and F1), the transgene was located only on
chromosome 11, short arm, region 1, band 2. It was stable and
integrated with genomic DNA (Fig. 4c, d). The transgene was
integrated as concatemers of an estimated 16 copies on chro-
mosome 11p12.
Flow cytometry
Flow cytometry was used for checking whether the transgene
expression results in the presence of functional !-galactosidase
responsible for removing terminal residues of !-D-galactose
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from the Gal!(1,3)Gal epitope, which, in consequence, should
be connected with the reduction of the Gal antigen level on the
surface of cells in pigs. Skin fibroblasts derived fromwild-type
animals, TG252 (F0) and TG1183 (F1), were used for the
analysis. Before the analysis of α-galactosidase functionality
on the protein level carried out bymeasuring the amount of Gal
antigen on the cell surface by flow cytometry, the enzyme
was labelled by BS-IB4 lectin conjugated with AlexaFluor
647 fluorochorme. BS-IB4 lectin isolated from Griffonia
simplicifolia (Bandeiraea simplicifolia) specifically binds
Gal antigen and the fluorescent intensity of AlexaFluor 647
allows for the determination of the relative amount of labelled
antigens on the surface of examined cells compared to non-
transgenic cells. The median values of fluorescence signals
from FL1 detector (AlexaFluor 647) are proportional to the
Gal epitope levels on the surface of the analysed cells.
Staining with BS-IB4 lectin showed a significant reduction
of fluorescence intensity in the case of fibroblasts from both
the founder from the F0 generation (TG252) as well as the
transgenic animal from the F1 generation compared to control
fibroblasts of wild-type animals. From the obtained results, it
can be concluded that the transgene integrated with genomic
DNA of pigs is fully functional, was incorporated into an
active transcription region and is expressed.
The analysis showed decreased levels of Gal antigen in
transgenic animals in F0 and F1 compared to wild-type ani-
mals. The reduction of Gal epitope expression was 58.21 %,
1 2 3 4 5            6







Fig. 2 Screening of the pGal-GFPBsd gene construct. Polymerase chain
reaction (PCR) was used to amplify DNA fragments of 464 bp and
861 bp. The separation of DNA fragments was conducted in 1.5 %
agarose gel. a Analysis of the integration with genomic DNA in pigs
(F0). Line 1, size marker (λ DNA/HindIII, EcoRI); lane 2, DNA isolated
from TG252; lane 3, DNA isolated from 253; lane 4, negative control
(without DNA); lane 5, negative control (wild-type pig DNA); lane 6,
positive control (pGal-GFPBsd gene construct). bAnalysis of integration
with genomic DNA in pigs (F1). Lanes 1–5 and 7–13, DNA isolated from
potentially transgenic pigs; line 6, size marker (λ DNA/HindIII, EcoRI);
line 14, negative control (wild-type pig DNA); line 15, negative control
(without DNA); line 16, positive control (pGal-GFPBsd gene construct)
Fig. 3 Southern blot hybridisation analysis to confirm transgenic ani-
mals and estimate of copies number. DNA (5.6 μg) isolated from
transgenic animals TG252, TG1183, TG1036 and TG1040, respectively,
carrying the pGAL-GFPBsd gene construct was digested with EcoRI and
hybridised with a probe of 464 bp. The probe was a 32P-dATP-labelled
PCR product of 464 bp formed on plasmid DNA (pGAL-GFPBsd) with
the use of the first pair of primers used for screening of the transgene. The
probe detects a 7.3-kb band that represents the pGAL-GFPBsd genetic
construct (black arrow). The red arrow probably indicates the band of
non-specific hybridisation of the probe. Lanes 1–4 contain DNA samples
from transgenic animals (TG252, TG1183, TG1036, TG1040); lane 5
wild-type pig DNA as a negative control; lanes 6–10 titration of the
transgene mixed with digested wild-type genomic DNA representing
133.12, 66.56, 33.28, 16.64 and 8.32 copies, respectively
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59.67 %, 56.67 % and 65.09 %. The level of Gal epitope
expression observed in F1 animals was similar to the F0 animal
(TG252). The fluorescence intensity decrease in TG252 was
2.59× in relation to the wild-type control, while for the pig
from F1 (in this study TG1183 and, additionally, TG1036 and
TG1040) was 2.86–2.31× (Fig. 5b). Additionally, fibroblasts
from cell lines derived from the TG1154 transgenic pig with
the expression of α1,2-fucosyltransferase, obtained by the
study group in the previous years (Lipiński et al. 2010),
were used for comparative analyses. For the transgenic pig
TG1154, a relative decrease of more than two and a half
(62.8 %) in the amount of Gal antigen on the cell surface
was observed in relation to the wild-type control, measured
by median values of fluorescence intensity after staining
with lectin BS-IB4 (Fig. 5a).
Human serum cytotoxicity test
Another test verifying the pGal-GFPBsd transgene function-
ality was the survival rate analysis of skin fibroblasts derived
from TG252 (F0) and TG1183 (F1) in comparison to the
survival rate of other wild-type cell lines in the presence of
human serum acting as a source of complement system ele-
ments. Activation of the complement system results in a
number of reactions which effect the formation of a complex
attacking the membrane. It is responsible for forming channels
Fig. 4 Cytogenetic analysis of animals expressing human α-galactosi-
dase. a Correct karyotype of a pig from the F0 generation, TG252 (38,
XY). b Correct karyotype of a pig from the F1 generation, TG1183 (38,
XX). c Post-hybridisation image of metaphase chromosomes from the
interphase nucleus of a cell line derived from skin fibroblasts of TG252.
Signal on chromosome 11q12. FITC-labelled marker, chromosomes and
nucleus stained by DAPI. d Post-hybridisation image of metaphase chro-
mosomes from a cell line derived from skin fibroblasts of the F1 pig.
Signal on chromosome 11q12. FITC-labelled marker, chromosomes
stained by DAPI
J Appl Genetics (2013) 54:293–303 299
in the cellular membrane that deform its structures through
changing lipid orientation and releasing liposomes. As a result
of the activity of the membrane-attacking complex, destruction
of the recognised cells takes place. Control medium contained
50% of inactivated human serumwhere the components of the
human complement system should not be active. This medium
was used as the toxicity control of compounds not belonging to
the complement system which were present in the human
serum. The survival rate analysis showed that there is no
statistically significant difference between the survival rate of
cells in the basic medium (A) and in the control medium (C),
so it is not the source of toxic compounds. The survival rate
was determined by the incubation of cell suspension with a
solution of trypan blue, a dye which penetrates the structure of
dead cells whose membrane is fragmented.
The analyses conducted for the test medium, where living
cells constituted only 22.05 % (+/−3.65 %), showed that the
compounds present in the serum affected adversely the sur-
vival rate of wild-type pigs compared to basic medium
(89.87 %, +/−6.09 %), with no elements of the human comple-
ment system. Similar comparative analysis conducted for a line
of fibroblasts derived from a transgenic animal (TG252) ex-
pressing α-galactosidase revealed a minor decrease of the cell
survival rate in test medium (91.67 %, +/−3.13 %) in relation to
the basic medium (98.53 %, +/−0.06%). Also, the cells derived
from TG1183 (F1) were characterised by high resistance to
elements of the human complement system present in human
serum. The survival rate was 97.23 % (+/−0.93 %) in the basic
medium without human serum and 93.37 % (+/−2.15 %) in the
test medium. A similar survival rate analysis was conducted for
a cell line derived from transgenic animal TG1154 expressing
!1,2-fucosyltransferase. The presence of transgene protected
the skin fibroblasts from the complement system activity and
the percentage loss of living cells was not significant. The
survival rate measured by an average number of living cells
compared to the total number of counted cells in 12 repetitions
amounted to 97.92 % (+/−1.17 %) in the basic medium and
92.35 %(+/−2.82 %) in the test medium (Fig. 6).
Discussion
One of the big challenges in xenotransplantation is that one
barrier needs to be totally resolved before the next is fully
unmasked. The complexity of processes responsible for ini-
tiating immunological reaction does not allow a one-
dimensional approach to xenotransplantation. Several strat-
egies need to be combined for obtaining an additive effect in
one transgenic organism in order to increase the chance of
stopping the immunological aggression against the cells of
the xenograft and its consequent survival. Modern genetic
engineering is facing a serious problem of producing, in the
shortest possible time, polytransgenic animals by interbreed-
ing monotransgenic animals or simultaneous transfection
with several transgenes in mono- or polycistronic transgene
expression. In the case of xenotransplantation, the opportunity
to develop and incorporate multiple genetic modifications
simultaneously will be limited until each mechanism is identi-
fied. It was proved that, in the case of coinjection of two similar























Fig. 5 Transgene expression analysis by flow cytometry. Fibroblasts
derived from the following animals were analysed: wild-type, pig
TG252 (F0), transgenic pigs F1 (TG1183, TG1036, TG1040), TG1154
expressing 1,2-fucosyltransferase labelled by BS-IB4 lectin (detects Gal
epitope), conjugated with AlexaFluor 647 fluorochrome. a The x-axis
shows the fluorescence intensity, the y-axis shows the number of cells
which were not labelled (black lines), labelled wild-type cells (red line),
transgenic animal TG252 (blue line) and transgenic animal TG1154 (green
line). The analysis showed decreased levels of Gal antigen in transgenic
animals compared to wild-type animals. The fluorescence fell by 58.9 %
for the pig withα-galactosidase (TG252) expression and by 62.8 % for the
pig with α1,2-fucosyltransferase (TG1154) expression compared to con-
trol. b The x-axis shows the fluorescence intensity, the y-axis shows the
number of cells which were not labelled (black lines), labelled wild-type
cells (red line), transgenic animal TG252 (F0) (light green line) and
transgenic animal TG1183 (F1) (dark blue line), transgenic animal
TG1036 (F1) (light blue line) and transgenic animal TG1040 (F1) (dark
green line). The analysis showed decreased levels of Gal antigen in
transgenic animals in F0 and F1 compared to wild-type animals. The
reduction of Gal epitope expression was, respectively, 58.21 %,
59.67 %, 56.67 % and 65.09 %. The level of Gal epitope expression
observed in the F1 animals was similar to the F0 animal (TG252)
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effectiveness similar to that observed in the case of single
transgenes introduced into two different animals (Jankowsky
et al. 2001; Goldman et al. 2004).
Hyperacute rejection of xenografts is the basic immuno-
logical limitation that makes transplanting animal organs in
humans unsuccessful. Experimental data and some clinical
experience show that there are three main directions that can
be followed: depletion of anti-pig antibodies by the devel-
opment of homozygous pigs for !1,3-galactosyltransferase
gene-knockout (GTKO), enzymatic removal of Gal!1,3-Gal
epitope or complement inhibition, or some combination of
these approaches (Pierson 2009). As we started our experi-
ments in 2002, there were several concerns about pigs with
the GTKO phenotype. First is the possible indispensability of
Gal in pigs and its essentiality for cellular function. Second is
the presence of another galactosyltransferase which is capable
of producing the Gal xenoantigen on glycolipids. And, finally,
the deletion of the Gal!1,3-Gal epitope would expose new,
potentially immunogenic antigens (Gock et al. 2011). In the
human organism, even 90 % xenoreactive antibodies recog-
nise the Gal!(1,3)Gal epitope, but there is still the remaining
10 % to be challenged. As a consequence, we chose two
strategies involving molecular modifications of the animal
genomes aiming at preventing the hyperacute rejection from
the immunological system. The first strategy described in this
study helps to prevent HAR by means of a reduction of the
epitope through the introduction and expression of a sequence
coding for !-galactosidase, which eliminates the effect of
!1,3-galactosyltransferase as a result of removing the terminal
!-D-galactose in the Gal!(1,3)Gal structure. Microinjection
allowed us to obtain a transgenic pig with an integrated,
functional and stable pGal-GFPBsd transgene. Both the trans-
genic hog TG252 as well as animals in the F1 generation were
characterised by a GLA expression level ensuring the derived
lines of fibroblast protection from the destructive human
complement system in the cytotoxicity test. The survival rate
in the medium containing human serum decreased by 7 % at
most, which suggests decreased reactivity in relation to trans-
genic pig cells. The observed decrease of the cell survival rate
may result from the fact that GLA, when removing the termi-
nal galactose from the surface of the Gal!(1,3)Gal structure,
exposes the unmodified residue of N-acetyllactosamine,
which may be a potential cryptoantigen causing immunolog-
ical response, irrespective of XNA (Watier et al. 1996). Flow
cytometry revealed a significant reduction of Gal antigen on
the surface of fibroblasts compared to the amount on the cell
surface of wild-type animals.
In previous studies, we focused on attempting to decrease
the level of Gal antigen synthesis on the surface of cells by
replacing it with a commonly accepted H antigen (0 antigen of
the ABO blood group system) by means of the expression of
functional human enzymeα1,2FT in transgenic pigs (Jura et al.
2004; Lipiński et al. 2010). Pigs carry an endogenous gene
coding for !1,2-fucosyltransferase; however, the H epitope
produced by this enzyme is not expressed on the endothelial
surface of blood vessels (Oriol et al. 1993; Sharma et al. 1996).
A high level of reduction in the synthesis of the Gal!(1,3)Gal
epitope observed in vivo on the surface of the endothelium is,
hence, an effect of artificially generated competition between
the endogenous !1,3GT and !1,2FT introduced experimental-
ly. The analysis we conducted showed a significant reduction in
Gal antigen on the surface of fibroblasts derived from trans-
genic animals, with additional copies of the !1,2FT gene
introduced to their genomes compared to the number of epi-
topes occurring on the surface of cells in wild-type animals.
The reduction of Gal antigen on the cell surface in transgenic
animals is, hence, a result of H transferees, which competes
with 1,3-galactosyltransferase for the acceptor molecule. It is
precisely correlated with the observed, increased levels of H
antigen (Jura et al. 2004; Lipiński et al. 2010).
We plan to interbreed the described transgenic animals and













Medium A Medium B
Nontransgenic TG252 TG1183 TG1154
Fig. 6 Survival rate analysis with standard deviations for cells from
wild-type animal (blue), from F0 (TG252) with !-galactosidase expres-
sion (red), F1 animal (TG1183) with !-galactosidase expression (green)
and TG1154 with the expression of !1,2-fucosyltransferase (purple)
measured in the basic medium and in test medium B containing 50 %
human serum. The survival rate was measured by an average number of
living cells compared to the total number of counted cells in 12 repeti-
tions. The percentage cell survival rate is shown on the y-axis
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and α-galactosidase. Through the combination of two modi-
fications, we will try to obtain the cumulative effect of
decreasing the level of Gal!(1,3)Gal epitope. The research
to date confirmed that GLA expression decreased the level
of Gal!(1,3)Gal epitope by 78 %, and the coexpression of !-
galactosidase and 1,2-fucosyltransferase eliminated it entirely
from the surface of SV40-immortalised aortic porcine endo-
thelial cells (PEDSV.15) (Jia et al. 2004). The enzyme !1,2FT
located within the medial compartment of the Golgi apparatus
cisterns shows its activity earlier than the trans endogenous
!1,3GT present in the trans compartment. The maturing oli-
gosaccharide, when migrating through the Golgi apparatus
from cis to trans compartments, cannot accept the terminal
galactose in a reaction catalysed by !1,3GT because of the
previous fucosylation of N-acetyllactosamine resulting from
!1,2FTactivity (Hartel-Schenk et al. 1991). The simultaneous
transformation of COS cells with !1,2FT and !1,3GT coding
genes showed the shift of the expression profile towards the
production of H epitope (Sandrin et al. 1995). The expres-
sion of !1,2FT does not result in total Gal!(1,3)Gal epitope
elimination, so introducing additional copies of genes coding for
!1,3GTwould supplement the activity of 1,2-fucosyltransferase.
Introducing gene coding for !-galactosidase removing the ter-
minal !-D-galactose should result in a further reduction of the
amount of functional Galα(1,3)Gal epitope formed as a result of
competition between !1,3GT and !1,2FT. Given that the effect
of GLA activity, when a solution of this enzyme is administered,
is transient, the integration of several strategies preventing HAR
is even more advisable. Regardless of the initial reduction in
the binding of IgM antibodies, after ex vivo perfusion of pig
kidneys with endo-β-galactosidase C solution, the resynthesis
of Gal!(1,3)Gal epitope on the cell surface and increased
XNA reactivity are observed. Obtaining a proper therapeutic
effect would be linked to the necessity of constant supplemen-
tation of the recipient with GLA solution (Ogawa et al. 2000).
More recently, Alexion Pharmaceuticals produced a combined
GTKOwith H-transferase transgenic pig to “compete out” any
potential antigen-producing transferases, including the putative
secondary galactosyltransferase (Ramsoondar et al. 2003).
Other strategies of preventing hyperacute rejection of
xenotransplants conducted in our team involve enzymatic regu-
lation of the complement system, which concerns blocking the
formation of membrane-attacking complex, and inactivation of
the !1,3GT gene responsible for the final Gal!(1,3)Gal structure
(unpublished data). The existence of genetic modifications en-
suring the expression of possibly the highest number of regula-
tors of the complement system and altering the distribution of
sugars on the surface of pig cells is quite likely to contribute to
both quantitatively and qualitatively limiting the use of pharma-
cological treatment, which weakens the immunological system
by blocking its functions. Only animals with numerous genetic
modifications obtained through the interbreeding of organisms
with single modifications or through cotransfection with several
gene constructs will become a reservoir of organs for medical
purposes (Cooper 2012).
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